Survey: Less than 10% AEs dubbed "serious;" Crucell lands UNICEF pediatric vaccine order;

> Half of surveyed drugmakers receive more than 1,000 adverse event reports per month; more than half of those report that fewer than 10 percent of their AE reports are serious. Article

> UNICEF has awarded Dutch biopharma Crucell an additional $110 million to supply its liquid pentavalent pediatric vaccine Quinvaxem to the developing world. Release

> In a partnership, Vetter will fill early-stage, high-value biopharmaceuticals at a Skokie, IL, developmental facility slated to open this fall, and Sentry will label, package and ship the clinical supplies from its site in Indianapolis. Article

> JHP Pharmaceuticals' sterile manufacturing site in Rochester, MI, has passed its GMP/pre-approval audit by the FDA drug center, following two thumbs-up last year from the regulator's biologics center and the European Medicines Agency. Release

> DSM Biologics has announced the successful scale up of its yield-boosting XD technology to 50 liters. Announcement

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.